企业名称绵阳乐运昇贸易有限公司法定代表人胡波注册资本950万人民币国标行业科学研究和技术服务 业>研究和试验发展>工程和技术研究和试验发展地址四川省绵阳市游仙区沈家坝街22号1栋5层1号507 室企业类型有限责任公司（非自然人投资或控股的法人独资）营业期限2025-8-6至无固定期限登记机关 绵阳市游仙区市场监督管理局 来源：金融界 序号股东名称持股比例1绵阳城东投资控股（集团）有限公司100% 经营范围含日用品销售；五金产品零售；针纺织品销售；建筑材料销售；通讯设备销售；食用农产品零 售。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动） 天眼查显示，近日，绵阳乐运昇贸易有限公司成立，法定代表人为胡波，注册资本950万人民币，由绵 阳城东投资控股（集团）有限公司全资持股。 ...

序号股东名称持股比例1湖北猇远能源集团有限公司100% 天眼查显示，近日，山东猇远医疗器械有限公司成立，法定代表人为常建波，注册资本1000万人民币， 由湖北猇远能源集团有限公司全资持股。 企业名称山东猇远医疗器械有限公司法定代表人常建波注册资本1000万人民币国标行业科学研究和技术 服务业>研究和试验发展>工程和技术研究和试验发展地址山东省菏泽市巨野县章缝镇章西村村南(巨野 聚通机械设备有限公司院内)企业类型有限责任公司(自然人投资或控股的法人独资)营业期限2025-8-6至 无固定期限登记机关巨野县市场监督管理局 来源：金融界 经营范围含第一类医疗器械生产；第一类医疗器械销售；第二类医疗器械销售；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；新材料技术推广服务；互联网销售（除销售需要许可的商 品）；医学研究和试验发展；劳务服务（不含劳务派遣）。（除依法须经批准的项目外，凭营业执照依 法自主开展经营活动）许可项目：第二类医疗器械生产；第三类医疗器械经营；医疗器械互联网信息服 务。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以相关部门批准文件 或许可证件为准） ...

Core Viewpoint - Aerospace Science and Technology Corporation (航天科技) has shown a significant stock price increase of 9.98% as of August 6, 2025, closing at 16.09 yuan, indicating positive market sentiment despite mixed financial performance [1] Financial Performance - The company's total revenue for Q1 2025 was 1.653 billion yuan, reflecting a year-on-year growth of 0.38% [1] - Net profit attributable to shareholders was 3.6467 million yuan, a decrease of 148.75% year-on-year [1] - The company's non-recurring net profit was 5.6905 million yuan, down 189.75% compared to the previous year [1] - Key financial ratios include a current ratio of 1.632, quick ratio of 1.046, and a debt-to-asset ratio of 48.89% [1] Market Activity - The stock had a turnover rate of 18.23% with a trading volume of 1.455 million hands and a transaction amount of 2.263 billion yuan [1] - Main capital inflow for the day was 76.5878 million yuan, accounting for 3.38% of the transaction amount [1] - Large orders saw a net inflow of 158 million yuan, while large and medium orders experienced net outflows of 81.1699 million yuan and 101.7973 million yuan respectively [1] Company Background - Aerospace Science and Technology Corporation was established in 1999 and is based in Harbin, focusing on research and experimental development [2] - The company has a registered capital of 7.98201406 billion yuan and a paid-in capital of 332.68971 million yuan [1][2] - The company has made investments in 13 enterprises and participated in 577 bidding projects, holding 6 trademarks and 505 patents [2]

Core Viewpoint - Recently, Fosun Pharma Industry Development (Chengdu) Co., Ltd. was established, focusing on medical research, drug testing instrument sales, and pharmaceutical equipment sales, fully owned by Fosun Pharma (600196) [2][3]. Company Information - The company is registered with a capital of 10 million RMB and has a business scope that includes medical research and experimental development, drug testing instrument sales, and sales of pharmaceutical specialized equipment [3]. - The legal representative is Yi Kexin, and the company is classified as a limited liability company with no fixed term of operation [3]. Business Scope - The general business activities include medical research and experimental development, drug testing instrument sales, pharmaceutical specialized equipment sales, packaging materials sales, and logistics services [3]. - The company is also involved in technology import and export, technical services, research and development, consulting, and technology transfer [3]. Regulatory Information - The company is registered with the Chengdu High-tech Zone Market Supervision Administration, and its business license is valid until July 30, 2025 [3].

Company Overview - 博媄生物科技（苏州）有限公司 has been established with a registered capital of 2 million RMB, fully owned by 西安博和医疗科技有限公司 [1] - The legal representative of the company is 罗惠娴 [1] Business Scope - The company’s business activities include technology services, development, consulting, and transfer, as well as sales of various medical devices and hygiene products [1] - Additional activities encompass retail and wholesale of cosmetics, daily chemical products, and information consulting services [1] Corporate Structure - 博媄生物科技 is classified as a limited liability company, specifically a法人独资 (wholly-owned by a legal entity) [1] - The company is located in 常熟市, 江苏省, within the 协同创新产业园 [1] Registration and Compliance - The company is registered with a business term extending until August 6, 2025, with no fixed expiration [1] - The registration authority is 常熟市数据局 [1]

Company Overview - Hubei Xueluo Food Technology Co., Ltd. has been established with a registered capital of 30 million RMB [1] - The legal representative of the company is Zhang Min, and it is wholly owned by Hubei Xueluo Enterprise Management Co., Ltd. [1] Business Scope - The company’s business scope includes technology services, development, consulting, exchange, transfer, promotion, agricultural scientific research, smart agriculture management, research and development of intelligent robots, park management services, and industrial engineering design services [1] - The company operates under the category of scientific research and technical services, specifically in engineering and technical research and experimental development [1] Registration Details - The company is registered with the market supervision administration of Qianjiang City, Hubei Province [1] - The business term is set from August 5, 2025, with no fixed expiration date [1] - The registered address is located at No. 21, Qianyuan Middle Road, Yujia Tai Community, Qianjiang City, Hubei Province [1]

天眼查商业履历信息显示，苏州苏试试验集团股份有限公司，成立于2007年，位于苏州市，是一家以从 事研究和试验发展为主的企业。企业注册资本50854.7806万人民币，实缴资本20608万人民币。公司法 定代表人为钟琼华。 金融界消息 截至2025年8月6日收盘，苏试试验（300416）报收于16.57元，上涨1.35%，换手率5.34%， 成交量26.96万手，成交金额4.45亿元。 资金流向方面，今日主力资金净流入5756.47万元，占比成交额12.93%。其中，超大单净流入1100.31万 元、占成交额2.47%，大单净流入4656.15万元、占成交额10.46%，中单净流出流入786.55万元、占成交 额1.77%，小单净流出6543.01万元、占成交额14.69%。 苏试试验最新一期业绩显示，截至2025中报，公司营业总收入9.91亿元、同比增长8.09%，归属净利润 1.17亿元，同比增长14.18%，扣非净利润1.14亿元，同比增长20.72%，流动比率1.714、速动比率 1.445、资产负债率42.02%。 通过天眼查大数据分析，苏州苏试试验集团股份有限公司共对外投资了26家企业，参与招投标项 ...

Group 1 - The stock price of Beifang Changlong (301357) closed at 157.9 yuan, an increase of 20.0% with a turnover rate of 54.13% and a trading volume of 128,800 hands, amounting to 1.892 billion yuan [1] - The net inflow of main funds today was 64.21 million yuan, accounting for 3.39% of the transaction amount, with large orders showing a net inflow of 83.52 million yuan [1] - The latest quarterly report shows total operating revenue of 20.569 million yuan, a year-on-year decrease of 16.86%, and a net profit attributable to shareholders of 5.0704 million yuan, a year-on-year decrease of 244.16% [1] Group 2 - Beifang Changlong New Material Technology Co., Ltd. was established in 2010 and is located in Xi'an, focusing on research and experimental development [2] - The company has made investments in 2 enterprises, participated in 29 bidding projects, and holds 25 trademark registrations and 145 patent registrations [2] - The company has a registered capital of 95.2 million yuan and a paid-in capital of 68 million yuan [1]

金融界消息 截至2025年8月5日收盘，圣诺生物（688117）报收于39.75元，下跌2.14%，换手率4.62%， 成交量7.28万手，成交金额2.89亿元。 资金流向方面，今日主力资金净流出3103.31万元，占比成交额10.73%。其中，超大单净流出2940.68万 元、占成交额10.17%，大单净流出162.63万元、占成交额0.56%，中单净流出流入897.03万元、占成交 额3.1%，小单净流入2206.28万元、占成交额7.63%。 天眼查商业履历信息显示，成都圣诺生物科技股份有限公司，成立于2001年，位于成都市，是一家以从 事研究和试验发展为主的企业。企业注册资本15738.5978万人民币，实缴资本5000万人民币。公司法定 代表人为文永均。 圣诺生物最新一期业绩显示，截至2025一季报，公司营业总收入1.84亿元、同比增长77.15%，归属净利 润4711.97万元，同比增长186.06%，扣非净利润4794.31万元，同比增长213.63%，流动比率1.216、速动 比率0.712、资产负债率41.96%。 通过天眼查大数据分析，成都圣诺生物科技股份有限公司共对外投资了11家企业，参 ...

Core Viewpoint - As of August 5, 2025, Qitian Technology (300061) reported a closing price of 12.68 yuan, experiencing a decline of 0.39% with a turnover rate of 2.37% and a trading volume of 146,800 hands, amounting to 186 million yuan in transaction value [1] Financial Performance - For the first quarter of 2025, Qitian Technology reported total operating revenue of 125 million yuan, a year-on-year decrease of 38.10% - The net profit attributable to shareholders was 2.83 million yuan, showing a year-on-year increase of 149.53% - The net profit excluding non-recurring items was 2.75 million yuan, reflecting a year-on-year growth of 135.96% - The current ratio stood at 1.542, the quick ratio at 1.538, and the debt-to-asset ratio at 57.92% [1] Company Overview - Qitian Technology Group Co., Ltd. was established in 1996 and is located in Shanghai, primarily engaged in research and experimental development - The company has a registered capital of 6.5899 billion yuan and a paid-in capital of 1.5565 billion yuan - The legal representative of the company is Li Tiansong [1] - According to data analysis, Qitian Technology has made investments in 13 enterprises, participated in 2 bidding projects, holds 71 trademark registrations, 8 patents, and possesses 23 administrative licenses [2]